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Abstract
IL-23p19 deficient mice have revealed a critical role of IL-23 in the development of experimental autoimmune diseases, such
as collagen-induced arthritis (CIA). Neutralizing IL-23 after onset of CIA in rats has been shown to reduce paw volume, but
the effect on synovial inflammation and the immunological autoimmune response is not clear. In this study, we examined
the role of IL-23 at different stages of CIA and during T cell memory mediated flare-up arthritis with focus on changes in B
cell activity and Th1/Th17 modulation. Anti-IL-23p19 antibody (anti-IL23p19) treatment, starting 15 days after the type II
collagen (CII)-immunization but before clinical signs of disease onset, significantly suppressed the severity of CIA. This was
accompanied with significantly lower CII-specific IgG1 levels and lower IgG2a levels in the anti-IL-23p19 treated mice
compared to the control group. Importantly, neutralizing IL-23 after the first signs of CIA did not ameliorate the disease. This
was in contrast to arthritic mice that underwent an arthritis flare-up since a significantly lower disease score was observed in
the IL-23p19 treated mice compared to the control group, accompanied by lower synovial IL-17A and IL-22 expression in
the knee joints of these mice. These data show IL-23-dependent and IL-23-independent stages during autoimmune CIA.
Furthermore, the memory T cell mediated flare-up arthritis is IL-23-mediated. These data suggest that specific neutralization
of IL-23p19 after onset of autoimmune arthritis may not be beneficial as a therapeutic therapy for patients with rheumatoid
arthritis (RA). However, T cell mediated arthritis relapses in patients with RA might be controlled by anti-IL-23p19 treatment.
Citation: Cornelissen F, Asmawidjaja PS, Mus AMC, Corneth O, Kikly K, et al. (2013) IL-23 Dependent and Independent Stages of Experimental Arthritis: No Clinical
Effect of Therapeutic IL-23p19 Inhibition in Collagen-induced Arthritis. PLoS ONE 8(2): e57553. doi:10.1371/journal.pone.0057553
Editor: Ivan Cruz Moura, Institut national de la sante´ et de la recherche me´dicale (INSERM), France
Received May 15, 2011; Accepted January 25, 2013; Published February 28, 2013
Copyright:  2013 Cornelissen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by an Erasmus MC research grant to E.L. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: Dr. Kikly is an employee of Eli Lilly and Company. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data
and materials.
* E-mail: E.Lubberts@erasmusmc.nl
Introduction
IL-23 is a heterodimeric cytokine consisting of a p40 subunit,
shared with IL-12, and a p19 subunit that is unique to IL-23 [1,2].
Together with the IL-12Rb1 receptor, the IL-23 receptor (IL-23R)
chain forms a functional receptor for IL-23 [3] that is expressed on
T cells, NK cells, monocytes and dendritic cells [1,3]. However,
IL-23R is not expressed on precursor T cells, suggesting that IL-23
signaling is not involved in the primary differentiation of naı¨ve T
cells [4]. The signaling of IL-12 and IL-23 leads to the activation
of both overlapping and divergent signal transduction pathways
and pathological roles in experimental arthritis [3]. IL-23 is
elevated in many autoimmune diseases, such as psoriasis,
rheumatoid arthritis (RA) and multiple sclerosis (MS) [5,6]. IL-
23 transgenic mice develop systemic inflammation, including
inflammation of the skin and small and large intestine [7],
highlighting the role of this pathway in promoting the activation of
effector T cells and sustaining of inflammatory tissue responses.
The role of IL-23 in the development of autoimmune collagen-
induced arthritis (CIA) has been shown using IL-23p19 knockout
mice. These mice did not develop CIA compared to IL-23
sufficient controls [8]. In these IL-23p19 deficient mice, no IL-17
producing cells were detected while the proportion of IFN-c
producing cells was unaltered [8]. This indicates that IL-23 is
involved in the generation of IL-17 producing T cells in vivo [2].
Furthermore, neutralizing IL-23 after onset of CIA in rats has
been shown to reduce paw volume [9], but the effect on synovial
inflammation and the immunological autoimmune response need
to be elucidated.
Here, we investigated the role of IL-23 during different stages of
autoimmune CIA by utilizing an IL-23p19 specific antibody.
When anti-IL-23p19 was given after CIA onset, arthritis severity
was not ameliorated. However, when anti-IL-23p19 was admin-
istrated after type II collagen (CII)-immunization but before
clinical CIA onset, significantly less severe disease was observed.
Finally, we show in a memory T cell dependent antigen-induced
arthritis model that IL-23 is essential for the development of flare-
up arthritis. In this model, synovial expression of IL-17A and IL-
22 but not IFN-c was markedly lower in the anti-IL-23p19 group
compared to control, highlighting the role of IL-23 in memory T
cell driven flare-up arthritis. Together, these data showed IL-23
dependent and independent stages during CIA and revealed that
IL-23 is not a critical factor during the effectors stage of CIA. In
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e57553
contrast, memory T cell mediated flare-up arthritis is IL-23
dependent.
Results
IL-23 does not Enhance CII-specific IL-17A Production by
CD4+ T cells
To profile the kinetics of Th1 and Th17 cells during collagen-
induced arthritis (CIA), splenocytes were isolated from type II
collagen (CII)-immunized DBA/1 mice at various time points
post-immunization (p.i.) and assessed for intracellular cytokines by
flow cytometry. At day 10 p.i. the highest proportions of total IL-
17A+ and IL-17A+IFNc- CD4+ T cells were observed as
compared to naı¨ve (non-immunized) mice as well as to mice 25
days p.i and CIA-diseased mice (Figure 1A). However, injection of
CFA only also induced a clear population of IL-17+IFNc- CD4+
T cells though lower than that observed in CII/CFA-immunized
mice. This shows the generation of CD4+ IL-17A-expressing T
cells during CIA.
Since IL-23p19 deficient mice revealed hardly any collagen
(CII)-specific IL-17 producing CD4+ T cells [8], we were
interested whether IL-23 is still required for CII-primed CD4+
T cells to produce IL-17A. Therefore, we evaluated the role of IL-
23 on CII-specific cytokine production by stimulating purified
CD4+ T cells taken from mice 10 days p.i. with CII/CFA
(Figure 1B). CII-specific restimulation led to a significant increase
of IL-17A secretion compared to non-restimulated CD4+ T cells.
No IL-23 levels could be measured in these cultures and adding
anti-IL-23p19 antibody had no effect on IL-17 production (data
not shown). However, adding IL-23 clearly enhanced the pro-
duction of IL-17A in both the non-restimulated and the CII-
restimulated cultures but no significant difference was observed
between both groups supplied with IL-23 showing that IL-23 does
not contribute to the production of CII-specific IL-17A. In-
terestingly, CII-specific restimulation did not enhance the secre-
tion of IFN-c in CD4+ T cells (Figure 1B), however, an increased
production of IFN-c was noted when IL-23 was added in the CII
restimulated CD4+ T cells compared to the un-restimulated
cultures (Figure 1B). Importantly and in contrast to the dominant
role of IL-23 in the development of collagen-specific CD4+IL-17+
T cells, these data suggest that IL-23 is not required for CII-
primed CD4+ T cells to produce IL-17A in contrast to IFN-c
upon antigen-specific restimulation.
Lower Severity of CIA after Neutralizing IL-23 during
Arthritis Onset
To investigate the role of IL-23 during different stages of CIA,
CII/CFA-immunized DBA/1 mice were randomly separated into
two groups and treated with a murine anti-murine IL-23p19
antibody or isotype control antibody at days 15, 22 and 29 p.i. At
day 21 p.i., a booster-injection was given according to our CIA
protocol. Significantly less severe CIA developed in the anti-IL-
23p19 treated group compared to control as assessed by the
arthritis score and statistically tested at each individual time point
over time by using the area under the curve (AUC), and
histologically (Figure 2A,B). The disease incidence was not
Figure 1. IL-23 does not enhance CII-specific IL-17A production. (A) DBA/1 mice were immunized with CFA only, with CII/CFA or left
untreated. At days 10 (CFA and CFA/CII) and 25 (CFA/CII) post-immunization, splenocytes were isolated and assessed for intracellular expression of IL-
17A and IFN-c. Numbers in quadrant indicate percentage positive cells in that quadrant. Plots are representative of n = 3–6 per group. (B) IL-17A and
IFN-c secretion levels after antigen (CII) specific restimulation of purified splenic CD4+ T cells with irradiated APCs in the absence (2) or presence of
exogenous IL-23. Data are the mean +SEM from n= 3 mice per group and *P,0.05; **P,0.01; ***P,0.001 as calculated by Mann-Whitney U test.
doi:10.1371/journal.pone.0057553.g001
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significantly different between the two groups and no difference in
the day of onset was observed (Figure 2A).
Reduced Levels of CII-specific Antibodies in Anti-IL-23p19
Treated Mice
To determine the effect of anti-IL-23p19 treatment on auto-
antibody production, serum was collected at day 35 and anti-CII-
specific IgG antibodies were measured. As shown in Figure 3,
IgG1 levels were significantly lower in the anti-IL-23p19 treated
group compared to controls. Additionally, IgG2a and IgG2b levels
were lower; however, no statistically significant difference was
reached.
No Therapeutic Effect of Neutralizing IL-23 after Onset of
CIA
Next, we asked whether anti-IL-23p19 has a therapeutic effect
in CIA. To evaluate this, mice were treated with anti-IL-23p19 or
control antibody weekly for 3 weeks after the first signs of CIA.
Anti-IL-23p19 did not significantly suppress the arthritis score,
compared with isotype control-treated mice (Figure 4A), and no
differences in anti-CII specific IgG antibody levels were noted
between the two groups (Figure 4B). To determine if longer
treatment with anti-IL-23p19 would lead to a significant improve-
ment in the arthritis score, anti-IL-23p19 or control antibody was
administrated for a period of 6 weeks after disease onset. However,
no ameliorative effect was observed (Figure 4C) after blockade of
IL-23 compared to control and this also did not affect the
production of anti-CII antibodies (Figure 4D). Together, these
data indicate that specific neutralization of IL-23 after CIA onset
has no beneficial effect on the CII-antibody titer or clinical score of
CIA.
IL-23 is Critically Involved in Memory T cell Mediated
Arthritic Flare
CIA pathology is initiated by CII-specific helper T and B cells
which in turn lead to the generation of anti-CII-specific IgG
producing plasma cells and the formation of pathogenic immune-
complexes (ICs) [10]. To further dissect the role of IL-23 on
reactivation of memory T cell mediated pathology, we utilized the
mBSA-driven antigen-induced arthritis (AIA) flare-up model. Mice
were immunized with mBSA/CFA and one week later an intra-
articular injection with mBSA was given to induce a primary
mono-arthritis which typically lasts for 3 weeks. After recovery
from the primary arthritis, mice received five weekly injections
with a murine anti-murine IL-23p19 antibody or isotype control
antibody. One day after the last antibody injection, a local arthritic
flare-up was induced by a second intra-articular injection with
mBSA and the following day mice were sacrificed and the arthritis
severity was assessed macroscopically. Mice treated with anti-IL-
23p19 developed significantly lower arthritis scores compared with
control (Figure 5A). To gain insight in the effect of IL-23
neutralization, RNA from knee-infiltrating cells was isolated and
gene transcription was determined by quantitative RT-PCR.
Synovial IL-17A and IL-22 expression was lower in anti-IL-23p19
treated mice compared to control, although not reaching statistical
significance (Figure 5B). In contrast, synovial IFN-c expression was
similar between the two groups (Figure 5B). These data show that
Figure 2. Administration of anti-IL-23p19 before onset prevents full-blown CIA. (A) DBA/1 mice were immunized with CII/CFA and three
weeks later mice received a booster-injection. On days 15, 22 and 29 either anti-IL-23p19 (filled squares) or control antibody (open circles) was given
intra-peritoneally. Macroscopic score (+SEM) and the average macroscopic score (average macroscopic score per individual mouse of all time points
assessed, assessed by student t-test) of n = 20 mice per group from 2 independent experiments is shown, as well as the incidence.
doi:10.1371/journal.pone.0057553.g002
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anti-IL-23p19 treatment significantly suppressed antigen-induced
flare-up arthritis.
Discussion
In the present study, we showed that anti-IL-23p19 antibody
treatment, started after the onset of CIA, did not ameliorate
arthritis severity. However, when anti-IL-23p19 antibody was
administrated after type II collagen (CII)-immunization but before
clinical signs of CIA onset, significantly less severe disease was
observed. Finally, we showed in a memory T cell dependent
antigen-induced arthritis model that IL-23 is essential for the
development of flare-up arthritis. In this model, synovial
expression of IL-17A and IL-22 but not IFN-c was lower in the
anti-IL-23p19 group compared to control, highlighting the role of
IL-23 in memory T cell driven flare-up arthritis.
Figure 3. Decreased production of anti-CII antibodies in mice treated with anti-IL-23p19. At day 35, at the end of the experiment as
shown in Figure 2A, serum was collected and anti-CII antibody levels of the IgG1, IgG2a and IgG2b subclasses were determined in sera. Data are
shown for each individual mouse or as the mean +SEM of n = 10 mice per group and *P,0.05; **P,0.01; ***P,0.001 as calculated by Mann-Whitney
U test.
doi:10.1371/journal.pone.0057553.g003
Figure 4. Neutralizing IL-23 after onset of CIA does not ameliorate disease activity. CIA was induced in DBA/1 mice and directly after the
first signs of CIA anti-IL-23p19 or control antibody was injected when an arthritis score between 0.5–1.5 was observed. (A and C) Arthritis severity was
scored macroscopically. Numbers on the x-axis indicate the day after the first injection with either antibody and the arrows indicate each time point
an injection was given. Data are from (A) n = 8 and (B) n = 10 mice per group. (B and D) At the end of each experiment, serum was collected and
anti-CII antibody production of the IgG1, IgG2a and IgG2b subclasses was measured.
doi:10.1371/journal.pone.0057553.g004
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In contrast to our observation that neutralizing IL-23p19 after
onset of CIA was not effective, Yago et al have claimed that anti-
IL-23 antibody administration after onset of CIA in rats
significantly reduced paw volume and attenuated CIA [9].
However, the data presented by these authors did not show
a significant difference in arthritis score between anti-IL-23 treated
rats and controls rats when they started treatment after onset of
CIA [9]. Here, in the present study we clearly showed in repeated
independent experiments no beneficial clinical effect of CIA when
anti-IL-23 was administered after CIA onset. This indicates that
IL-23 is not critical during this stage of CIA. Interestingly and in
line with our mouse data is a recent phase IIa, randomized,
double-blind, placebo-controlled trial of an IL-12/IL-23 inhibitor
in patients with rheumatoid arthritis that showed no clinical
improvement in RA [11]. However, it has been shown that IL-
17A is still involved in the pathophysiology of CIA at this stage of
the disease and IL-17 blocking in RA looks promising [12–14].
This may indicate uncoupling of the IL-23/IL-17A axis during
this stage of CIA and further studies will be needed to examine this
hypothesis.
Murphy et al. have shown that IL-23 is critical in the formation
of CD4+IL-17+ T cells [8]. In the present study, we showed that
IL-23 is redundant for the maintenance of CII-specific IL-17A
production in autoimmune arthritis. We found the highest
proportion of splenic IL-17A-expressing CD4+ T cells 10 days
after CII/CFA-immunization, showing that immunization with
type II collagen (CII) induced the generation of Th17 cells.
However, IL-23 is not required for CII-primed IL-17-producing
CD4+ T cells to produce IL-17 after Ag-specific re-stimulation
since IL-23 levels could not be measured and neutralization of IL-
23 had no effect on IL-17 production (data not shown). In
addition, adding IL-23 after the formation of CII-specific IL-17A-
producing cells did not specifically enhance IL-17A in contrast to
IFN-c levels.
In vivo neutralizing IL-23 after CII immunization but before
the onset of CIA significantly suppressed the severity of the disease.
This was examined during the stage of CIA where CII-specific
CD4+ IL-17+ T cells were already formed which is quite different
compared to the IL-23p19 deficient mice, since these knock-out
mice lack IL-17A-expressing CD4+ T cells from the start [8].
Neutralizing IL-23p19 after the induction of CII-specific of IL-
17A-expressing CD4+ T cells did not prevent the onset of CIA as
was described for the IL-23p19 deficient mice [8], and no
difference was noted in disease incidence between anti-IL-23p19
treated mice and the control group. However, mice that developed
CIA showed a significantly lower severity than control mice,
indicating that IL-23 is involved in the regulation of disease
progression during this stage of CIA. Another plausible explana-
tion for the reduced disease severity in mice treated with anti-IL-
23p19 before CIA onset is the potential role of IL-23 in the
generation of pathogenic Th17 cells [15–17]. IL-23 suppresses IL-
10 production by IL-6/TGFb-differentiated Th17 cells [18] as
well as from ex-vivo isolated CII-primed CD4+ T cells (Lubberts
et al., unpublished observations). Additionally, exogenous IL-23
enhances the production of IL-17A and IL-22 by CD4+ CII-
primed T cells by down-regulating T-bet and FoxP3 and up-
regulating RORct [19]. Altogether, this strongly suggests that IL-
23 drives full maturation of pathogenic Th17 cells in vivo.
Whether the Th17 cells have less pathogenic behavior after
neutralizing IL-23p19 is at present under investigation.
The levels of CII-specific IgG’s were influenced after neutral-
izing IL-23 during onset of CIA. Both IgG1 and IgG2a/2b were
lowered indicating no specific regulation of B cell activity. From
this study it is not clear whether IL-23 had a direct effect on B cell
activity and CII-specific IgG formation or indirectly. No difference
in expression of B cell activation factors such as BAFF and APRIL
were noted (data not shown). In contrast, no difference in the levels
of CII-specific IgG’s was noted after blocking IL-23 after onset of
CIA which was accompanied with no clinical improvement of the
disease during this stage of CIA. Thus, neutralizing IL-23 before
disease onset effectively suppressed disease severity whereas anti-
IL-23p19 treatment of mice after CIA onset did not ameliorate
disease. This strongly suggests IL-23-dependent and -independent
stages of CIA. In experimental autoimmune encephalomyelitis
(EAE; a mouse model for human multiple sclerosis), however, anti-
IL-23p19 effectively ameliorated EAE when treatment was started
at disease onset, peak of disease, or even during the first remission
(Kikly et al., unpublished data). This difference in therapeutic
efficacy of anti-IL-23p19 may be explained by the fact that the
later stages of EAE autoimmunity are highly T cell dependent as is
Figure 5. IL-23 plays a critical role in the arthritis flare-up reaction. In C57BL/6 mice, antigen-induced arthritis (AIA) was induced. Four weeks
after the induction of AIA either IgG control or anti-IL-23p19 was administrated intra-peritoneally weekly for 5 weeks. One day after the final injection
mice were given an intra-articular injection with mBSA to induce a flare-up or were left untreated. (A) Twenty-four hours later, knee joints were
assessed macroscopically on a 0–2 scale. Each symbol represents data from an individual knee joint and the horizontal line depicts the median. Data
are from n= 5 mice per group assessing both knee joints. *P,0.05; **P,0.01; ***P,0.001 by Mann-Whitney U test. (B) Cells from the knee-joints
were isolated, RNA was extracted and gene expression for the indicated genes was quantified by quantitative RT-PCR and normalized for GAPDH.
Data are the mean+SEM from 5 mice per group.
doi:10.1371/journal.pone.0057553.g005
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less so in CIA. Indeed, our current data suggests that neutralizing
IL-23 mainly dampens T cell activity and the lower anti-CII
antibodies in mice treated with anti-IL-23p19 before, but not after
onset of CIA highlighting the role of IL-23 on T cell dependent B
cell activation [20].
To further dissect the role of IL-23 on memory T cell
dependent pathology, we used an antigen-induced arthritic
(AIA) flare-up model in which memory T cells are responsible
for joint inflammation [21]. Previously, we have shown that the
primary antigen-induced arthritis (AIA) model is IL-23/IL-17
mediated, since IL-23p19- as well as IL-17RA-deficient mice
were protected from progressive joint inflammation [22,23].
Here, we started treatment of anti-IL-23p19 antibody after the
primary AIA was declined and no clinically joint inflammation
was observed. Persistent blocking of IL-23 activity before
inducing the AIA flare-up significantly prevented the expression
of severe joint inflammation with lower synovial mRNA
expression of IL-17A and IL-22. This shows that memory T
cell driven flare-up arthritis is IL-23-dependent, a phenomenon
comparable to the prevention of EAE relapses with anti-IL-
23p19 or anti-IL-23R [16,24].
In summary, we have shown IL-23-dependent and IL-23-
independent stages during autoimmune CIA. IL-23 is not a critical
factor during the effector stage of CIA. In contrast, the memory T
cell mediated flare-up arthritis is IL-23-mediated. These data
suggest that specific neutralization of IL-23 using an anti-IL-23p19
antibody after onset of autoimmune arthritis may not be beneficial
as a therapeutic therapy for RA patients. However, T cell
mediated arthritis relapses in patients with RA might be controlled
by anti-IL-23p19 treatment.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations of the Dutch Animal ethics committee. The
in vivo study protocol was approved by the Committee on the
Ethics of Animal Experiments of the Erasmus MC (DEC nr. 128-
10-03).
Collagen-induced Arthritis
Male DBA/1 mice (Harlan, Horst, the Netherlands) were
immunized intradermally with (100 mL of 1 mg/mL) bovine
collagen type 2 (CII) (Chondrex) emulsified in complete Freund’s
adjuvant (CFA). On day 21, mice were given an intra-peritoneal
(i.p.) injection of 100 mg CII in PBS. CIA severity was assessed as
previously described [12].
Mice were given 100 mg neutralizing murine IgG1 anti-murine
IL-23, p19 specific (anti-IL-23p19) or murine IgG1 isotype control
antibody i.p. on days 15 (before disease onset), 22 and 29. For anti-
IL-23p19 antibody, the IC50 is 60 ng/ml as determined in
a mouse splenocyte assay stimulated with mouse IL-23 and as
a read out IL-17A was measured by ELISA in the culture
supernatant. The BIAcore affinity determination at 37uC degrees
gave a KD of 100 pM. The 3 mg/kg/week dose (i.p.) gave the
best neutralization of disease progression in EAE (personal
communications with Dr. K. Kikly). Alternatively, mice were
observed daily and as soon as an arthritis score of 0.5–1.5 was
observed, 100 mg anti-IL-23p19 or isotype control antibody was
injected i.p. weekly for 3 or 6 weeks. All experiments were
approved by the Dutch Animal ethics committee (DEC), protocol
128-10-03.
Assessment of Collagen-induced Arthritis
Mice were considered to have arthritis when significant changes
in redness and/or swelling were noted in the digits or in other
parts of the paws. Arthritis was scored visually using the following
scale: 0, noninflamed; 1, mild inflammation; 1.5, marked
inflammation; 2, severe inflammation. Scoring was done by two
independent observers, without knowledge of the experimental
groups (9).
Antigen-induced Arthritis
To induce antigen-induced arthritis (AIA), methylated BSA
(mBSA, 8 mg/mL) was emulsified in an equal volume of CFA
containing 1 mg/mL heat-killed M. tuberculosis (H37Ra;
Difco). C57BL/6 Mice were immunized intradermally with
100 mL mBSA/CFA. One week later, 30 mg mBSA was injected
intra-articular to induce mono-arthritis. Four weeks after the
induction of the mono-arthritis, 100 mg anti-IL-23p19 or control
antibody was injected ip, weekly for 5 weeks. Finally, one day
after the last injection of anti-IL-23p19, a local arthritic flare
was induced by injecting 2 mg mBSA intra-articular. One day
later, mice were sacrificed and the severity of arthritis in the
knee joint was scored macroscopically on a scale of 0–2 after
removing the skin (0, no inflammation; 1, mild inflammation; 2,
severe inflammation).
Anti-collagen Antibody ELISAs
To determine anti-CII-specific antibodies, wells of microtiter
plates were coated with 1 mg/mL CII, washed and blocked with
10% FCS. Samples and a reference-sample were serially diluted.
Wells were washed, incubated with goat-anti-mouse IgG1, IgG2a
or IgG2b-biotinylated antibodies (0.5 mg/mL) (Southern Bio-
technology Associated, Inc.) and optical density at 450 nm was
measured.
Levels of IL-17A (R&D Systems, Minneapolis, MN, USA) and
IFN-c (BD OptEIATM, BD Biosciences, Sunnyvale, CA, USA)
were measured by ELISA according to the manufacturers’
instructions.
Isolation of Ankle Infiltrating Cells
Ankles were cut into smaller pieces and put into 5 mL serum-
free medium containing 0.65 Wu¨nsch units Liberase TM Re-
search Grade (Roche Applied Science, Indianapolis, In, USA).
After 2 hours, cells were pushed through a 100 mm filter and these
ankle-cells were processed for further use.
Flow Cytrometric Analyses
For intracellular detection of cytokines, cells were stimulated
with PMA (0.05 mg/mL; Sigma-Aldrich) and Ionomycin (0.5 mg/
mL; Invitrogen) in the presence of GolgiStopTM (BD Biosciences,
Sunnyvale, CA, USA) for 4 h. Cells were fixed using 2% PFA and
permeabilized with 0.5% saponin (Sigma-Aldrich). Cells were
stained with CD4-PerCP-Cy5.5 (RM4-5), IL-17A-Pe (TC11-
18H10) and IFN-c-Pe-Cy7 (XMG1.2) (all BD Pharmingen).
Samples were acquired on a BD FACS CANTO II flow cytometer
and analyzed using FlowJo (Tree Star, Inc.) software.
Quantitative PCR
Total RNA of splenocytes was extracted, and DNaseI-treated
RNA was used for cDNA synthesis (8). PCR primers were
designed manually or using ProbeFinder software (Roche Applied
Science, Indianapolis, In, USA) and probes were chosen from the
Universal probe library (Roche Applied Science) (Table 1).
Quantitative realtime PCR was performed using the ABI Prism
Neutralizing IL-23 during Experimental Arthritis
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7900HT sequence-detection system (Applied Biosystems, Foster
City, CA, USA) and analyzed using SDS v2.3 software (Applied
Biosystems). The Ct values obtained were normalized to those of
glycereraldehyde-3-phosphate dehydrogenase (GAPDH).
In vitro Restimulation Assay
Splenocytes 10 days after bovine CII-immunization DBA/1
mice were isolated. MACS-isolated (negative selection using
CD11b, GR-1, CD8, Ter119, TCRcd, B220 and NK1.1
biotinylated antibodies) CD4+ T cells at a 4:1 ratio with 50 Gy
irradiated APCs were cultured for 3 days in the presence or
absence of 50 mg/mL bovine CII with or without 50 ng/mL IL-23
(R&D Systems). After culture, cytokines were measured in
supernatant by ELISA.
Statistical Analyses
Differences between groups were tested with the Mann-Whitney
U test. P values less than 0.05 were considered significant. Error
bars are presented as standard error of the mean (SEM).
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Table 1. Primers used in this study.
Gene Sequence (59 to 39) Probe nr*
Gapdh F: AGCTTGTCATCAACGGGAAG
R: TTTGATGTTAGTGGGGTCTCG
9
Il17a F: TTTCCTGACCAAACTCAGCA
R: TTCATTGTGGAGGGCAGAC
34
Il22 F: TTTCCTGACCAAACTCAGCA
R: CTGGATGTTCTGGTCGTCAC
17
*refers to the Roche Universal probe library kit.
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